U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07849309) titled 'Real-World Incidence of Intraocular Inflammation Following Intravitreal Treatment With Aflibercept 8 mg' on Sept. 24.
Brief Summary: Aflibercept 8 mg is a high-concentration anti-vascular endothelial growth factor therapy developed to extend treatment intervals for retinal diseases while maintaining the efficacy and safety of aflibercept 2 mg. Phase 3 trials supported its use in neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
The aim of this study was to estimate the incidence of intraocular inflammation (IOI) after intravitreal aflibercept 8 mg injections in an unselected cohort tre...